Yttrium-90 SIRT in NET

Sander C. Ebbers; Arthur J.A.T. Braat; Marnix G.E.H. Lam

doi:10.1007/978-3-030-70773-6_20

Yttrium-90 SIRT in NET

Sander C. Ebbers^*
, Arthur J.A.T. Braat
, Marnix G.E.H. Lam

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

Abstract

During the past two decades, selective internal radiotherapy (SIRT, i.e., radioembolization) is being increasingly applied in patients suffering from unresectable hepatic metastases of neuroendocrine tumors (NET). Essentially, SIRT consists of administering microscopic spheres into the arterial vasculature of the liver. The treatment is increasingly used in patients liver-dominant disease, and can result in prolongation of survival while retaining quality of life. Current research mainly focusses on improved patient selection and optimization of dosimetry, thereby reducing healthy liver tissue damage and increasing tumor response.

Original language	English
Title of host publication	Liver Intra-arterial PRRT with 111In-Octreotide
Subtitle of host publication	The Tumoricidal Efficacy of 111In Auger Electron Emission
Publisher	Springer International Publishing
Pages	231-239
Number of pages	9
ISBN (Electronic)	9783030707736
ISBN (Print)	9783030707729
DOIs	https://doi.org/10.1007/978-3-030-70773-6_20
Publication status	Published - 30 May 2021

Access to Document

10.1007/978-3-030-70773-6_20

978-3-030-70773-6_20Final published version, 750 KBLicence: Taverne

Cite this

@inbook{a77578f5b5ab4be596beb169036bc461,

title = "Yttrium-90 SIRT in NET",

abstract = "During the past two decades, selective internal radiotherapy (SIRT, i.e., radioembolization) is being increasingly applied in patients suffering from unresectable hepatic metastases of neuroendocrine tumors (NET). Essentially, SIRT consists of administering microscopic spheres into the arterial vasculature of the liver. The treatment is increasingly used in patients liver-dominant disease, and can result in prolongation of survival while retaining quality of life. Current research mainly focusses on improved patient selection and optimization of dosimetry, thereby reducing healthy liver tissue damage and increasing tumor response.",

author = "Ebbers, \{Sander C.\} and Braat, \{Arthur J.A.T.\} and Lam, \{Marnix G.E.H.\}",

note = "Funding Information: This work was mainly supported by the Global Frontier R\&D Program (2013M3A6B1078875) at the Center for Hybrid Interface Materials (HIM) funded by the Ministry of Science, Information \& Communication Technology (ICT) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2014R1A2A1A13050479). Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021.",

year = "2021",

month = may,

day = "30",

doi = "10.1007/978-3-030-70773-6\_20",

language = "English",

isbn = "9783030707729",

pages = "231--239",

booktitle = "Liver Intra-arterial PRRT with 111In-Octreotide",

publisher = "Springer International Publishing",

address = "Switzerland",

}

TY - CHAP

T1 - Yttrium-90 SIRT in NET

AU - Ebbers, Sander C.

AU - Braat, Arthur J.A.T.

AU - Lam, Marnix G.E.H.

N1 - Funding Information: This work was mainly supported by the Global Frontier R&D Program (2013M3A6B1078875) at the Center for Hybrid Interface Materials (HIM) funded by the Ministry of Science, Information & Communication Technology (ICT) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2014R1A2A1A13050479). Publisher Copyright: © Springer Nature Switzerland AG 2021.

PY - 2021/5/30

Y1 - 2021/5/30

N2 - During the past two decades, selective internal radiotherapy (SIRT, i.e., radioembolization) is being increasingly applied in patients suffering from unresectable hepatic metastases of neuroendocrine tumors (NET). Essentially, SIRT consists of administering microscopic spheres into the arterial vasculature of the liver. The treatment is increasingly used in patients liver-dominant disease, and can result in prolongation of survival while retaining quality of life. Current research mainly focusses on improved patient selection and optimization of dosimetry, thereby reducing healthy liver tissue damage and increasing tumor response.

AB - During the past two decades, selective internal radiotherapy (SIRT, i.e., radioembolization) is being increasingly applied in patients suffering from unresectable hepatic metastases of neuroendocrine tumors (NET). Essentially, SIRT consists of administering microscopic spheres into the arterial vasculature of the liver. The treatment is increasingly used in patients liver-dominant disease, and can result in prolongation of survival while retaining quality of life. Current research mainly focusses on improved patient selection and optimization of dosimetry, thereby reducing healthy liver tissue damage and increasing tumor response.

UR - https://www.scopus.com/pages/publications/85150480645

U2 - 10.1007/978-3-030-70773-6_20

DO - 10.1007/978-3-030-70773-6_20

M3 - Chapter

AN - SCOPUS:85150480645

SN - 9783030707729

SP - 231

EP - 239

BT - Liver Intra-arterial PRRT with 111In-Octreotide

PB - Springer International Publishing

ER -

Yttrium-90 SIRT in NET

Abstract

Access to Document

Other files and links

Fingerprint

Cite this